… -to-severely active ulcerative colitis [OASIS], etrasimod 2 mg provided significant benefit
versus placebo and was generally well tolerated. This open-label extension [OLE] evaluated …

… with severe steroid-resistant ulcerative colitis. The placebo-… of severe steroid-resistant active
ulcerative colitis. In the placebo … with steroid-refractory ulcerative colitis; the response rate in …

… Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative
colitis. We present final data from OCTAVE Open, an open-label, long-term extension study. …

… ulcerative colitis. METHODS: Fifteen patients with mild to moderately active ulcerative colitis
despite therapy with 5-aminosalicylic acid compounds were enrolled in an open-label study …

… , open-label trial compared ciclosporin with infliximab in patients admitted to hospital with
severe colitis. … and had an acute severe flare of ulcerative colitis defined by a Lichtiger score of …

Background The aim of this study was to assess the clinical benefit and tolerability of
adalimumab, a fully human monoclonal antibody to tumor necrosis factor (TNF), in patients with …

… use of oral Qing-Dai in the treatment for ulcerative colitis (UC) patients. Studies exploring …
Methods: The open-label, prospective pilot study was conducted at Keio University Hospital. …

… In this mixed methods, open-label, pragmatic randomised … , unscheduled, with severe
ulcerative colitis and failed to … from the Crohn's and Ulcerative Colitis Questionnaire (CUCQ) …

… and efficacy of ozanimod in patients with moderately to severely active ulcerative colitis [UC]
with ≥ 4 years of follow-up in the phase 2 TOUCHSTONE open-label extension [OLE]. …

… Objective GO-COLITIS aimed to measure the effectiveness of subcutaneous golimumab in …
ulcerative colitis (UC) despite conventional treatment. Design GO-COLITIS was an open label…